[{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LB1148","moa":"Serine protease","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Seneca Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Seneca Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Yuma Regional Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Yuma Regional Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Yuma Regional Medical Center"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Newsoara","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Giiant pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Palisade Bio \/ Palisade Bio"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palisade Bio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Palisade Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of moderate to severe ulcerative colitis.

                          Brand Name : PALI-2108-Prodrug

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 07, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 31, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 25, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 05, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 08, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 29, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration with Strand Life Sciences grants Palisade Bio access to an advanced lead program, PALI-2108, which is currently in the early stages of trials for treating Ulcerative Colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 21, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Strand Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. It is being evaluated for the treatment of ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 21, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The company will use the net proceeds to continue developing its lead asset, PALI-2108, a microbiota-activated PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.

                          Brand Name : PALI-2108

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 07, 2024

                          Lead Product(s) : PALI-2108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Ladenburg Thalmann

                          Deal Size : $4.0 million

                          Deal Type : Public Offering

                          blank